scholarly journals PD13-01 USE OF ADVANCED PRACTICE PROVIDERS TO IMPROVE PATIENT ACCESS IN UROLOGY

2018 ◽  
Vol 199 (4S) ◽  
Author(s):  
Melody Chen ◽  
Jonathan Kiechle ◽  
Zachary Maher ◽  
Christopher Gonzalez
2019 ◽  
Vol 6 (3) ◽  
pp. 151-154
Author(s):  
Melody Chen ◽  
Jonathan Kiechle ◽  
Zachary Maher ◽  
Christopher Gonzalez

2020 ◽  
pp. 019459982097292
Author(s):  
Nita Sharma ◽  
David Upjohn ◽  
Carrlene Donald ◽  
Katie E. Zoske ◽  
Chelsea L. Aldridge ◽  
...  

Objective Advanced practice providers (APPs) may see patients independently or assist in “collaborative” clinics in otolaryngology practices. Our goal was to redesign the collaborative physician-APP clinic model to increase patient access, maintain financial sustainability, and optimize patient and staff experience. Methods The study was performed in a tertiary care academic rhinology clinic seeing adult patients. The DMAIC framework (define, measure, analyze, improve, control) was used to develop the new model. The process shift between old and new models was analyzed by utilizing a statistical process control chart. Patient and staff surveys were tracked. Results The collaborative physician-APP model was redesigned into 2 parallel and independently run (“concurrent”) physician and APP clinics. Patient access increased by 38.9% from a mean of 17.9 patients per collaborative clinic (n = 15 days, 269 patients) to 29.3 patients per concurrent clinic (n = 12 days, 352 patients). Medicare reimbursement rate modeling showed the collaborative clinic to operate at a loss of $1341.51 per day, while the concurrent clinic model operated at a $1309.88 gain (200% positive change). Patient and staff experience tracked positively. Discussion Otolaryngology clinics can become overwhelmed by the volume of empaneled established patients. Traditional collaborative physician-APP clinics see the same panel of patients together. However, these can be successfully redesigned to a concurrent model. Concurrent clinics improve patient access and provider satisfaction while maintaining patient satisfaction and fiscal performance. Implications for Practice Leveraging an experienced APP to run a parallel and independent clinic alongside the physician (concurrent clinic model) may improve patient access, financial metrics, and patient/staff experience.


Pharmaceutics ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 48
Author(s):  
Ioana Gherghescu ◽  
M. Begoña Delgado-Charro

Biosimilar medicines expand the biotherapeutic market and improve patient access. This work looked into the landscape of the European and US biosimilar products, their regulatory authorization, market availability, and clinical evaluation undergone prior to the regulatory approval. European Medicines Agency (EMEA, currently EMA) and Food and Drug Administration (FDA) repositories were searched to identify all biosimilar medicines approved before December 2019. Adalimumab biosimilars, and particularly their clinical evaluations, were used as a case study. In the past 13 years, the EMA has received 65 marketing authorization applications for biosimilar medicines with 55 approved biosimilars available in the EU market. Since the first biosimilar approval in 2015, the FDA has granted 26 approvals for biosimilars with only 11 being currently on the US market. Five adalimumab biosimilars have been approved in the EU and commercialized as eight different medicines through duplicate marketing authorizations. Whilst three of these are FDA-approved, the first adalimumab biosimilar will not be marketed in the US until 2023 due to Humira’s exclusivity period. The EU biosimilar market has developed faster than its US counterpart, as the latter is probably challenged by a series of patents and exclusivity periods protecting the bio-originator medicines, an issue addressed by the US’s latest ‘Biosimilar Action Plan’.


2020 ◽  
Vol 23 ◽  
pp. S610
Author(s):  
L.H. Cheung ◽  
A. Chaupin ◽  
S. Duttagupta

Author(s):  
Melissa E. Cyr ◽  
Daryl Boucher ◽  
Ashley A. Holmes ◽  
James C. Benneyan

2021 ◽  
Vol 44 (2) ◽  
pp. 129-135
Author(s):  
Jamila Wynter ◽  
Shelley Hurwitz ◽  
John R. Saltzman ◽  
Jennifer Nayor

Author(s):  
Seung-Lai Yoo ◽  
Dae-Jung Kim ◽  
Seung-Mi Lee ◽  
Won-Gu Kang ◽  
Sang-Yoon Kim ◽  
...  

This study reviews and evaluates the national drug formulary system used to improve patient access to new drugs by making reimbursement decisions for new drugs as part of the South Korean national health insurance system. The national health insurance utilizes three methods for improving patient access to costly drugs: risk-sharing agreements, designation of essential drugs, and a waiver of cost-effectiveness analysis. Patients want reimbursement for new drugs to be processed quickly to improve their access to these drugs, whereas payers are careful about listing them given the associated financial burden and the uncertainty in cost-effectiveness. However, pharmaceutical companies are advocating for drug prices above certain thresholds to maintain global pricing strategies, cover the costs of drug development, and fund future investments into research and development. The South Korean government is expected to develop policies that will improve patient access to drugs with unmet needs for broadening health insurance coverage. Simultaneously, the designing of post-listing management methods is warranted for effectively managing the financial resources of the national health insurance system.


Sign in / Sign up

Export Citation Format

Share Document